Abstract 4464: Repurposing nebivolol with CPI-613 for triple-negative breast cancer: Linking <i>in-vitro</i> synergy to <i>in-vivo</i> exposure.
Mikayla Skillman(University of Houston), Diana S.-L. Chow(University of Houston), Benny Abraham Kaiparettu(Baylor College of Medicine), Airong Li(University of Houston), Junhyoung Park(Baylor College of Medicine), Meghana V. Trivedi(University of Houston), Amir Mohammad-Gholizadeh(University of Houston), Fatima Dagher(University of Houston)
Cited by 0
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133